> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gilead Ends AML Trial of Magrolimab
- URL: https://www.fdaweb.com/gilead-ends-aml-trial-of-magrolimab/
- Published: 2023-09-27T12:00:00.000Z
- Updated: 2026-09-14T18:58:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155426

Gilead Sciences has ended its ENHANCE-2 trial of magrolimab in acute myeloid leukemia (AML) with TP53 mutations. A company [statement](https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-the-discontinuation-of-magrolimab-study-in-aml-with-tp53-mutations?ref=fdaweb.com) says that based on an ad hoc analysis and following review by an independent data monitoring committee, Gilead concluded that magrolimab is unlikely to demonstrate a survival benefit in AML with TP53 mutations compared to standard of care.

There were no new safety signals identified, the statement says.